Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology

The 2019 consensus statement emphasizes the importance of managing cutaneous adverse events in chemotherapy patients to prevent treatment interruptions and preserve patient quality of life. It details various skin toxicities, such as hand-foot syndrome, epidermal necrolysis, and chemotherapy-induced alopecia, and their management strategies, including dose adjustments and supportive dermatological treatments. The document calls for collaboration between oncologists and dermatologists to effectively diagnose and treat these toxicities. It also discusses the use of toxicity scales like CTCAE and PRO-CTCAE for standardizing the reporting of adverse events. The statement concludes that proper management of skin toxicities is crucial for maintaining patient quality of life and treatment efficacy, and highlights the role of body image in patient tolerance of disease and therapy. No human or animal studies were conducted for this document.